We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Celgene broke its losing streak Monday with a positive clinical trial showing for Revlimid, and one analyst thinks more rosy pipeline events could follow in the not-too-distant future.